Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

Fig. 5

A PFS in EGFR-mutant NSCLC patients in different age groups (age ⩾75 years vs. age < 75 years) treated with 2nd G EGFR-TKIs; B TTFs in EGFR-mutant NSCLC patients in different age groups (age ⩾75 years vs. age < 75 years) treated with 2nd G EGFR-TKIs. EGFR, epidermal growth factor receptor; PFS, progression-free survival; TTF, time to treatment failure

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us